Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra + Chemo in Resectable PDAC
NCT02550327Phase 1Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jan 2016
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anakinra in pancreatic ductal adenocarcinoma (PDAC), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Disease Free Survival at 2 years. Started Jan 2016; status: completed.
02
Drugs
anakinra
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02550327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550327.